Colorectal cancer is still extraordinarily uncommon in children, yet the disease is appearing in young patients more often—and with alarming severity. U.S. cases among children, teenagers and very young adults have reportedly increased roughly sixfold over the past two decades, even as rates among many older adults decline. The rising pediatric cancer trend is now pushing researchers to investigate everything from delayed diagnosis to the gut microbiome.
New findings presented at the American Academy of Pediatrics’ 2026 National Conference examined medical records for 84 patients aged 21 or younger, diagnosed between 2012 and 2023 at 34 institutions. The study, conducted through the Pediatric Surgical Oncology Research Collaborative, found a median diagnosis age of 16.5 years. Most tumors were colon adenocarcinomas, while the remainder began in the rectum. The American Academy of Pediatrics said the cohort was limited to patients without a previously identified genetic colorectal-cancer syndrome or inflammatory bowel disease, offering a look at apparently sporadic cases.
The numbers point to a disease that is frequently discovered only after it has advanced. Fifty-one percent of the patients had Stage III cancer and another 29% had Stage IV disease. More than one-third experienced a relapse, and 45.2% died from colorectal cancer by the end of the study period. The pathology was often aggressive: poorly differentiated tumors, mucinous features and signet-ring characteristics were all common, particularly among patients whose cancer later returned.
Symptoms were present for a median of 12 weeks before diagnosis, with abdominal or lower-back pain reported most often. Changes in bowel habits, unexplained weight loss and rectal bleeding were also frequent. Those signs can be mistaken for constipation, gastrointestinal infections or other problems because clinicians and families quite reasonably view colorectal cancer as an unlikely explanation in a teenager. Yet the study found that only about 20% of patients had a first- or second-degree relative with colorectal cancer, meaning family history alone would not have identified most of the cases.
The broader age shift is part of the mystery. The American Cancer Society says colorectal-cancer incidence is rising by about 3% annually among adults ages 20 to 49, while rates are falling among people 65 and older; routine screening and removal of precancerous polyps likely contribute to the older group’s decline. Researchers are examining whether changing diets, sedentary lifestyles and other environmental exposures could be influencing younger generations, but those factors remain associations rather than proven causes.
Much of the current investigation is focused on the gut microbiome—the vast community of microorganisms involved in digestion and immune regulation. A disruption known as dysbiosis could promote chronic inflammation and potentially contribute to DNA damage, but scientists caution that the relationship is complex and unlikely to yield one simple culprit. For now, the practical message is more immediate: persistent abdominal pain, rectal bleeding, unexplained weight loss or major bowel changes deserve medical attention at any age, including during adolescence. The pediatric findings also underscore the need for closer coordination between adult and pediatric cancer teams as more early-onset cases emerge.
